DDInter431 DDInter899
Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Colchicine {u} (Compound) resembles {v} (Compound) Trimethobenzamide
Colchicine {u} (Compound) treats {v} (Disease) gout
Colchicine {u} (Compound) binds {v} (Gene) SLC22A3
Colchicine {u} (Compound) upregulates {v} (Gene) RAP1GAP
Colchicine {u} (Compound) palliates {v} (Disease) systemic scleroderma
Colchicine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Interactions
Colchicine {u} (Compound) downregulates {v} (Gene) AKR7A2
Colchicine {u} (Compound) causes {v} (Side Effect) Asthenia
Colchicine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phenylpropanolamine
Colchicine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Colchicine (Compound) resembles Trimethobenzamide (Compound)
Colchicine (Compound) treats gout (Disease)
Colchicine (Compound) binds SLC22A3 (Gene)
Colchicine (Compound) upregulates RAP1GAP (Gene)
Colchicine (Compound) palliates systemic scleroderma (Disease)
Colchicine (Compound) is included by P-Glycoprotein Interactions (Pharmacologic Class)
Colchicine (Compound) downregulates AKR7A2 (Gene)
Colchicine (Compound) causes Asthenia (Side Effect)
Colchicine may cause a minor interaction that can limit clinical effects when taken with Phenylpropanolamine
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib